With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
Residual breast cancer after neoadjuvant chemotherapy has worse prognosis, especially triple-negative breast cancer. In the CREATE-X trial published yesterday in NEJM, patients with HER2(-) tumors and residual disease at surgery were randomized +/- to 6-8 cycles of adjuvant capecitabine (aka Xeloda). Five year disease-free survival (DFS) improved from 68% to 74% and overall survival (OS) from 84% to 89% with the addition of Xeloda. These effects were particularly promising in the triple-negative subset (HR for DFS 0.58 and for OS 0.52). Radiation was allowed to go before or after capecitabine, which will be an important logistical point in clinical practice.